<p class="abstract"><strong>Background:</strong> Dermatophytosis is the most common fungal infection, which has recurrent and persisting course because of topical steroid abuse, irregular treatment and poor hygiene. Dermatology life quality index (DLQI) is a questionnaire based survey method to assess the impact and severity of many dermatology specific diseases and infections. There is paucity in the literature on the impact of dermatophytosis on the quality of life (Qol). The aim of the study was to assess the impact of dermatophytosis and its sequelae on quality of life.</p><p class="abstract"><strong>Methods:</strong> A total of 186 patients with recurrent and persistent dermatophytosis were selected for Qol questionnaire for a period of six months and statistical analysis was performed using t test to determine the impact of dermatophytosis on Qol.<strong></strong></p><p class="abstract"><strong>Results:</strong> Male to female ratio was 2.7:1, most cases were between 25 to 45 years age group. Thigh fold and gluteal region were the most common sites involved. Mean DLQI score was 12.7. The DLQI scores were statistically influenced by age of the patient, duration of the infection and site of involvement.</p><p class="abstract"><strong>Conclusions:</strong> This study revealed significant impairment of Qol in dermatophytosis patients. Assurance and counselling along with early and prompt treatment plays a significant role in reducing disease related psychosocial sequelae and increase the efficacy of treatment.</p>

No abstract

Purpose: To test the hypothesis that a systematic, combination treatment of patients with oculocutaneous albinism type 1 (OCA 1) results in improvement in multiple measures of visual and ocular motor function.Methods: This is a prospective, interventional case series analysis of clinical and electrophyisological data before and after multimodal visual system therapy in 85 patients with OCA 1 who had no previous treatment. Therapy included a three step approach after adaptation to spectacle correction: 1) extraocular muscle surgery, 2) contact lens correction, 3) oral baclofen (Lioresal R ). Outcome measures included: 1) routine demography and clinical characteristics, 2) binocular best-corrected visual acuity in the null position (BVA), 3) gaze dependent visual acuity (GDVA), 4) primary position strabismic deviation (SD), 5) anomalous head posture (AHP), 6) contrast sensitivity function (CS), and 7) the expanded nystagmus acuity function (eNAFX). All patients were followed at least 12 months. Parametric and nonparametric statistical analysis of outcome measure data above pre-and post-treatment were perfomed using standard software on grouped data using computerized software.Results: Patient age ranged from 3.6 to 43.1 years (average 16 years). 63% were male. Follow up ranged from 12-50 mos (ave 15.1 mos). 7% had an associated systemic diagnosis, 95% had a significant refractive error, 88% percent had an AHP, 36% had a periodic or aperiodic component to their nystagmus. 97% had strabismus. There were no serious complications from surgery with a reoperation rate of 12%. There were signficant post treatment improvements in mean/median group BVA, GDVA, SD, AHP, CS, and eNAFX. Conclusion:This study supports the hypothesis that using a combination of standard optical, medical and surgical treatments in patients with OCA1 will result in improvements in multiple aspects of ocular motor and visual functions.Synopsis: This study demonstrates how using a combination of standard medical, optical and surgical therapy results in improvements in ocular motor and visual functions in patients with OCA1.

<p class="abstract">Imatinib mesylate (IM) is a tyrosine kinase inhibitor approved for chronic myeloid leukemia, gastrointestinal stromal tumor and few dermatological conditions such as dermatofibrosarcoma protruberans, systemic sclerosis and systemic mastocytosis among other conditions. It is known to cause non lichenoid eruptions commonly and rarely it can cause lichenoid drug eruption. Small plaque parapsoriasis is a monoclonal T cell disorder with clinical similarity to psoriasis characterised by small sized plaques with digitate appearance.We report a case of 75 year old male on IM for gastrointestinal stromal tumor who presented with clinical features suggestive of small plaque parapsoriasis which was eventually proved as lichenoid drug eruption secondary to IM on biopsy. IM was identified as the offending drug and the eruptions subsided one month after discontinuation of the drug.</p>

No abstract